A practical reference on Maillard reaction: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
Peptide size distribution is central to product characterization because biological and functional effects often depend on molecular weight. Size-exclusion chromatography, reversed-phase high-performance liquid chromatography, and capillary electrophoresis can separate peptides by size or hydrophobicity. Mass spectrometry provides sequence-level information and can detect marker peptides, though it is less common for routine lot release. For allergen control, enzyme-linked immunosorbent assays estimate residual intact protein or specific milk proteins, but results depend on antibody recognition and may not detect small peptides. No single method captures the full composition.
Stability and storage practices affect measured quality over time. Hydrolysate powders are hygroscopic and can absorb moisture, leading to caking, Maillard browning, and reduced solubility. Cool, dry storage in sealed containers limits these changes, while high humidity and warm temperatures accelerate them. Microbiological testing for total aerobic counts, yeasts, molds, and specified pathogens is typical for food ingredients. Regulatory status varies by country; in many jurisdictions hydrolyzed whey protein is regulated as a food ingredient rather than a drug, and claims about reduced allergenicity require specific substantiation.
Quality control for whey protein hydrolysate begins with verifying protein content, moisture, ash, and fat using standard food analysis methods. Total nitrogen by Kjeldahl or Dumas combustion gives an estimate of protein, often calculated with a dairy-specific conversion factor. Amino acid analysis after acid hydrolysis quantifies individual residues but destroys tryptophan and may convert glutamine and asparagine. The extent of peptide bond cleavage is usually estimated by measuring free amino groups, soluble nitrogen, or trichloroacetic acid-soluble peptides. These tests are operationally defined and can give different results across laboratories.
Regulatory status differs by country and intended use. In many jurisdictions, whey protein hydrolysate is regulated as a food ingredient, while specific infant formula or medical food uses may require additional review. Labeling rules govern protein content claims, allergen statements, and terms such as partially hydrolyzed or extensively hydrolyzed. Analytical methods for degree of hydrolysis are not fully standardized, so values can depend on the assay. This variability makes direct comparison between products difficult unless the method and reference material are stated.
Quality control for whey protein hydrolysate begins with specification of protein, moisture, ash, fat, lactose, and degree of hydrolysis, while molecular weight distribution is measured by size-exclusion chromatography or electrophoresis. Free amino acid content can be quantified by amino acid analysis. Microbial limits, heavy metals, and residual enzyme activity are also monitored. Because hydrolysis conditions influence batch consistency, manufacturers validate processes and test each lot against release criteria. Sampling plans and reference standards help compare results across laboratories.
Storage stability depends on moisture, temperature, oxygen, and packaging, and hydrolysates are hygroscopic and can cake when exposed to humid air. Maillard reactions between peptides and residual lactose can cause browning and flavor changes during warm storage, while lipid oxidation may develop if residual fat is present. Cool, dry conditions and sealed containers slow these reactions. Shelf-life studies typically monitor moisture, color, solubility, molecular weight profile, and microbial counts over time. Accelerated tests estimate stability, but real-time data remain the reference for shelf-life assignment.
| Property | Value | Notes |
|---|---|---|
| Protein content | 70–90% dry basis | Depends on starting isolate or concentrate and filtration. |
| Moisture | ≤6% typical | Higher moisture increases caking and browning risk. |
| Hydrolysis extent | 4–20% common range | Values vary by assay and product type. |
| Peptide size | Mostly below 10 kDa in extensive hydrolysates | Distribution depends on enzyme and time. |
| Common analytical method | Size-exclusion HPLC | Estimates molecular weight distribution. |
Quality control includes verifying identity, protein content, degree of hydrolysis, and absence of contaminants. Because hydrolysates are often used in foods and supplements, regulations may treat them as food ingredients rather than drugs. Allergen labeling rules can vary, and highly hydrolyzed products are sometimes considered less allergenic, but this depends on peptide size and clinical testing. Sourcing documents should link each lot to raw whey, enzymes, and processing conditions. Independent verification is useful because analytical results can shift with method and laboratory.
Laboratories characterize whey protein hydrolysate using several complementary methods. Nitrogen determination estimates total protein, while size-exclusion chromatography and mass spectrometry reveal peptide size distributions. Degree of hydrolysis can be calculated from free amino groups, pH change, or osmolarity, but each approach has assumptions. Moisture, ash, and mineral content are also measured because they affect shelf life and reconstitution. No single test fully describes a hydrolysate, so specifications usually combine several results.
Quality control for hydrolysates often includes allergen and contaminant checks. Because whey is a milk-derived ingredient, milk protein residues may remain, and the extent to which hydrolysis reduces allergenic potential is product-specific and not fully predictable. Tests may screen for heavy metals, melamine, pesticides, and microbial indicators. Enzyme residues and processing aids are also monitored when regulations require it. Batch-to-batch consistency is assessed through peptide mapping or functional tests, since small process changes can alter taste, solubility, or nutritional performance.
Laboratories characterize whey protein hydrolysate by several complementary methods. Total nitrogen or Kjeldahl analysis estimates crude protein, while amino acid analysis gives a more detailed composition. Size-exclusion chromatography and mass spectrometry separate peptides by molecular weight and can reveal the distribution of chain lengths. Degree of hydrolysis is often calculated from free amino groups using trinitrobenzenesulfonic acid or o-phthaldialdehyde assays. No single measurement captures all relevant properties, so specifications usually combine protein content, peptide profile, moisture, ash, and microbial limits.
Storage stability depends on moisture, temperature, oxygen, and packaging. Dry hydrolysate powders are typically stable for months to years when kept cool and sealed, but they can absorb water and cake if exposed to humid air. Higher temperatures accelerate Maillard reactions between peptides and residual sugars, leading to browning and flavor changes. Lipid oxidation can occur if residual fat is present, producing off-odors. Once a powder is reconstituted, microbial growth becomes a concern, so liquid forms require refrigeration or other preservation steps.
Hydrolysate powders are hygroscopic and can absorb moisture during storage, which may promote caking, browning, and loss of solubility. Cool, dry conditions and sealed packaging slow these changes, while high humidity and warm temperatures accelerate Maillard reactions between peptides and residual sugars. Liquid hydrolysates are more perishable and often require refrigeration or preservatives. Shelf-life studies usually monitor moisture, color, solubility, free amino groups, and microbial load over time. Stability depends on residual lactose, water activity, packaging barrier properties, and the initial peptide profile.
Degree of hydrolysis is commonly estimated by titrating liberated carboxyl groups, measuring soluble nitrogen in trichloroacetic acid, or using o-phthaldialdehyde assays. Molecular weight distribution is often examined by size-exclusion chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis, or mass spectrometry. These methods answer different questions: titration estimates bond cleavage, while chromatography describes peptide size ranges. Because no single reference method is universally applied, values reported by different laboratories may not be directly comparable. Method details such as calibration standards and sample preparation strongly influence results.
Routine quality control for hydrolysate powders includes total nitrogen or protein content by Kjeldahl or Dumas combustion, moisture by oven or Karl Fischer titration, ash, and mineral profiles. Microbiological tests typically cover total aerobic counts, yeasts, molds, and specified pathogens according to regional food safety rules. Amino acid analysis can quantify free amino acids and peptide-bound residues after hydrolysis. For products intended for special populations, additional tests may target residual lactose, fat, or specific allergenic proteins. Specifications are set by the manufacturer and may exceed general food-grade requirements.
A sector-type mass analyzer uses a static electric and/or magnetic field to control the path of the ion beam. The most common type uses a magnetic field. In a simplified case, the field is a constant field
Stress may result from rough handling, washing and immersion in water, or transport (e.g., during shipping), which may in some cases contribute to mortality. Inbreeding depression can result in reduced physical health for farmed insects and producers generally make efforts to maintain a more genetically diverse population. Insects may be fed toxin-contaminated grains or plastics/polymers that may reduce their health, depending on the level of inclusion and specific types of these ingredients used (though this is not expected to be common practice in the industry currently).
=== Expansion === The company opened locations in Arizona in 2000 and added new restaurants in Reno, Sparks, and Carson City, Nevada, in late 2004. In-N-Out became a huge success in these new locations. In late December 2005, In-N-Out's 200th location was opened in Temecula, California. In 2007, it opened its first restaurant in Tucson, Arizona. The store opening broke company records for the most burgers sold in one day and the most sold in one week. In 2008, In-N-Out expanded into a fourth state by opening a location in Washington, Utah, a suburb of St. George. By late 2009, the chain expanded into northern Utah with three new locations situated in Draper, American Fork, and Orem. More locations opened in the spring of 2010 in West Valley City, West Jordan, Centerville, and Riverton. In 2013, In-N-Out opened a distribution center in Las Vegas to serve mountain area restaurants.
Genetic screens conducted in Drosophila led to the identification of several proteins that play a central role in Notch signaling, including Enhancer of split, Master mind, Delta, Suppressor of Hairless (CSL), and Serrate. At the same time, the Notch gene was successfully sequenced and cloned, providing insights into the molecular architecture of Notch proteins and led to identification of Notch homologs in Caenorhabditis elegans (C. elegans) and eventually in mammals. In the early 1990s Notch was increasingly implicated as the receptor of a previously unknown intercellular signal pathway in which the Notch intercellular domain (NICD) is transported to the nucleus where it acts as a transcription factor to directly regulate target genes. The release of the NICD was found to be as a result of proteolytic cleavage of the transmembrane protein through the actions of the γ-secretase complex catalytic subunit Presenilin. This was a significant interaction as Presenilin is implicated in the development of Alzheimer's disease. This and further research into the mechanism of Notch signaling led to research that would further connect Notch to a wide range of human diseases.
Creatine methyl ester is the methyl ester derivative of the amino acid creatine. It can be prepared by the esterification of creatine with methanol. By undergoing an esterification process with methanol, this compound seeks to enhance creatine's absorption rate in the body. Creatine esters, like creatine methyl ester, have been studied for their potential to improve bioavailability when compared to standard creatine monohydrate.
Sources: en.wikipedia.org
Their father, Nathan Rothschild, 1st Baron Rothschild, head of the English branch of the family, had a guarded attitude towards Zionism, but he died in March 1915 and his title was inherited by Walter. Prior to the declaration, about 8,000 of Britain's 300,000 Jews belonged to a Zionist organisation. Globally, as of 1913 – the latest known date prior to the declaration – the equivalent figure was approximately 1%.
=== Predatory vs. defensive bites === Snake bites are classified as either predatory or defensive. During defensive strikes, the rate of venom expulsion and total volume of venom expelled is much greater than during predatory strikes. Defensive strikes can have 10 times as much venom volume expelled at 8.5 times the flow rate. This can be explained by the snake's need to quickly subdue a threat. While employing similar venom expulsion mechanics, predatory strikes are quite different from defensive strikes. Snakes usually release the prey shortly after the envenomation allowing the prey to run away and die. Releasing prey prevents retaliatory damage to the snake. The venom scent allows the snake to relocate the prey once it is deceased. The amount of venom injected has been shown to increase with the mass of the prey animal. Larger venom volumes allow snakes to effectively kill larger prey while remaining economical during strikes against smaller prey. This is an important skill as venom is a metabolically expensive resource.
On 4 March, at the Extraordinary Arab Summit in Cairo on Developments in the Palestinian Issue, Arab leaders adopted a $53 billion plan proposed by Egypt that did not involve displacing Palestinians from the Strip. The plan was to create an interim committee of "independent, professional Palestinian technocrats" to govern Gaza to prepare for the Palestinian Authority’s return. Hamas said that it would not bring its own candidates to the proposed governing committee but that it would need to give its permission in regards to the committee’s tasks, members and agenda. Mahmoud Abbas said that he would be prepared to hold elections, which Hamas welcomed. The summit released an AI-enhanced presentation showing modern housing developments, as well as blueprints for resorts and attractions. The plan was to seek international funding. The plan outlines a six-month phase of recovery providing temporary housing for 1.5 million displaced Palestinians within seven sites in Gaza, followed by a two-stage reconstruction program: a two-year first stage of $20 billion and a 2.5 year second stage of $30 billion. The New York Times reported the funding for the plan remains unclear as Gulf states will be reluctant to invest in rebuilding Gaza only to see it destroyed again if violence returns. The Israeli foreign ministry said the plan had "outdated" outlooks and rejected the plan's dependence on the Palestinian Authority, adding that Hamas would be given power by the plan.
== Others == Endogenous: Adrenomedullin Apelin Asprosin Bombesin Calcitonin Carnosine CART CLIP DSIP Enteroglucagon Formyl peptide GALP GIP GRP Integrin ligands (collagens, fibrinogen, fibronectin, laminins, ICAM-1, ICAM-2, osteopontin, VCAM-1, vitronectin) Kininogens Motilin Natriuretic peptides (ANP, BNP, CNP, urodilatin) Nesfatin-1 Neuromedin B Neuromedin N Neuromedin S Neuromedin U Obestatin Osteocalcin Resistin Secretin Thymopoietin Thymosins Thymulin Urotensin-II VGF Exogenous: Lifitegrast (LFA-1 antagonist)
Tax incentives Exclusivity (enhanced patent protection and marketing rights) Research subsidies Creating a government-run enterprise to engage in research and development as in a Crown corporation A 2015 study of "34 key Canadian stakeholders, including drug regulators, funders, scientists, policy experts, pharmaceutical industry representatives, and patient advocates" investigated factors behind the pharmaceutical industry growing interest in "niche markets" such as orphan drugs.
Sources: en.wikipedia.org
=== Neurodegeneration === Pathological protein aggregation is a major hallmark of multiple neurodegenerative diseases. O-GlcNAc on various proteins has been found to play roles in suppressing protein aggregation, motivating clinical efforts to inhibit OGA and elevate cellular O-GlcNAc levels. This strategy is being evaluated by companies for Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, and amyotrophic lateral sclerosis (ALS). Multiple companies have advanced OGA inhibitors into the clinic including Alectos Therapeutics, Asceneuron, Biogen, Eli Lilly, and Merck.
Such an inflexible dosing regime limits the utility benzodiazepines offer in practice; e.g. lorazepam and alprazolam can be used as needed for situational anxiety in which continuous use is unnecessary or excessive, while clonazepam can be titrated to response when continuous relief is indicated, up to a maximum of 4 mg a day, four times greater than the dose used in comparison with etifoxine over the 24 week duration of the trial. In general, they offer a degree of personalization that is not possible with etifoxine. Indeed, better evidence is required before etifoxine can be said to replace benzodiazepines in practice, especially considering the trials above were relatively small in size, along with the high attrition rates and lack of personalization of the benzodiazepines used. The usual dosage of etifoxine (as the hydrochloride salt) is 150 to 200 mg per day in divided doses of 50 to 100 mg two to three times per day (e.g., 50 mg–50 mg–100 mg). It is taken for a few days to a few weeks, but no longer than 12 weeks.
=== Commercialization === Elbasvir/grazoprevir was FDA approved in the United States, and has been approved for use in the European Union, Canada, Japan, Australia, Saudi Arabia, Israel, and Switzerland. Zepatier is one of a few non-interferon therapies that are market-available. Competing treatments include Gilead's Harvoni (sofosbuvir and ledipasvir) and AbbVie's Viekira Pak (ombitasvir, paritaprevir, and ritonavir). Sale projections for Zepatier are $636 million in 2016 and rising to $1.5 billion by 2020. With Merck's release of Zepatier early in 2016, they saw large bumps in share prices in quarters 1 and 2, but are expected to drop down a bit. Zepatier does not have as strong a market hold as other competitive HCV treatments.
== Awards and honors == 2023- Women's Empowerment Influencer Award Icahn School of Medicine at Mount Sinai 2017 – Elected Fellow of the American Society for Cell Biology 2015 – Senior Leadership Award of the Women in Cell Biology of the American Society for Cell Biology, named the Sandra K. Masur Leadership Award 2008 – Jacobi Medallion, Mount Sinai Alumni Association 2007 – Rosalind Franklin Society Invited Member of Founding Board 2001 Women in Medicine Silver Achievement Award, Association of American Medical Colleges 1997 Outstanding Woman Scientist – Association for Women in Science, Metropolitan New York Chapter 1997 Lew R. Wasserman Merit Award 1996 Outstanding Faculty Achievement Award 1978 Brotherhood Education Award, Conference of Christians and Jews
== Laboratory methods == Hemoglobin A2 has a crucial role in screening and diagnosis of the beta-thalassemia trait. Various laboratory methods exist, each providing different outcomes of accuracy. The different quantification methods of HbA2 relies on how effective it can be separated from other hemoglobin variants. Various laboratory methods are employed, such as cation exchange high-performance liquid chromatography (HPLC), microcolumn chromatography, and cellulose acetate electrophoresis with elution. At first, cellulose acetate electrophoresis was utilized to measure HbA2, but this process proved to be too time-consuming and labor-intensive, making it impractical for large examinations or samples. Similar efficiency issues were encountered with other methods like IEF and scanning densitometry. These two methods separate proteins based on their isoelectric point. Chromatography, another commonly used method, demonstrated reliability in diagnosing individuals with the beta carrier gene. However, this method was also time-consuming and inefficient when dealing with large sample numbers. Out of the various methods, the one that accurately measures HbA2 is HPLC. It is a reliable technique because it's able to accurately determine HbA2, HbF, and Hb variants. The various different Hb variants include: HbS, HbE, Hb Lepore, HbC, HbD and HbO-Arab. There are several different factors that can contribute to the quantification of HbA2 to be inaccurately measured.
Sources: en.wikipedia.org
Hydrolysis extent is commonly estimated by quantifying free amino groups or soluble nitrogen after protein cleavage. The result is expressed as a percentage of cleaved peptide bonds. Different assays use different definitions and may not agree exactly.
It shows the relative amounts of peptides falling into size ranges, such as below 1 kDa or above 10 kDa. This profile can relate to taste, solubility, and potential allergenicity. It is more informative than hydrolysis extent alone.
No single routine method resolves every peptide in a hydrolysate. Chromatography and mass spectrometry provide complementary views, but complex mixtures remain incompletely characterized. Testing usually targets specified attributes rather than the entire peptide inventory.
Methods include trinitrobenzenesulfonic acid assay, o-phthaldialdehyde assay, formol titration, and nitrogen solubility. Values depend on calibration and assay conditions. Results should be interpreted with the stated method.